M-J. Ahn

1.1k total citations
68 papers, 622 citations indexed

About

M-J. Ahn is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, M-J. Ahn has authored 68 papers receiving a total of 622 indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Pulmonary and Respiratory Medicine, 49 papers in Oncology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in M-J. Ahn's work include Lung Cancer Treatments and Mutations (51 papers), Colorectal Cancer Treatments and Studies (19 papers) and Cancer Immunotherapy and Biomarkers (18 papers). M-J. Ahn is often cited by papers focused on Lung Cancer Treatments and Mutations (51 papers), Colorectal Cancer Treatments and Studies (19 papers) and Cancer Immunotherapy and Biomarkers (18 papers). M-J. Ahn collaborates with scholars based in South Korea, United States and Spain. M-J. Ahn's co-authors include Solange Peters, Pasi A. Jänne, Dongwook Kim, David Planchard, Ramona F. Swaby, Enriqueta Felip, Byoung Chul Cho, Ezra E.W. Cohen, Satoru Kitazono and Hong Zebger‐Gong and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Thoracic Oncology.

In The Last Decade

M-J. Ahn

67 papers receiving 617 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M-J. Ahn South Korea 14 517 394 118 105 93 68 622
Eduardo J. Pennella United States 11 416 0.8× 377 1.0× 82 0.7× 89 0.8× 62 0.7× 33 578
Emily Roarty United States 10 348 0.7× 330 0.8× 79 0.7× 54 0.5× 138 1.5× 24 480
Virginia Palomar Coloma France 4 421 0.8× 190 0.5× 42 0.4× 118 1.1× 48 0.5× 5 481
Sufia Safina Russia 9 272 0.5× 249 0.6× 85 0.7× 40 0.4× 45 0.5× 28 397
Maria Bassanelli Italy 10 419 0.8× 326 0.8× 99 0.8× 57 0.5× 68 0.7× 23 547
Beung‐Chul Ahn South Korea 12 497 1.0× 366 0.9× 106 0.9× 106 1.0× 81 0.9× 38 621
María Gión Spain 13 484 0.9× 298 0.8× 124 1.1× 53 0.5× 98 1.1× 70 654
Nathan Comeaux United States 4 444 0.9× 308 0.8× 42 0.4× 134 1.3× 36 0.4× 9 559
A. Sandler United States 16 524 1.0× 390 1.0× 120 1.0× 74 0.7× 80 0.9× 35 604
L. Bouhlel France 5 530 1.0× 397 1.0× 52 0.4× 80 0.8× 161 1.7× 7 621

Countries citing papers authored by M-J. Ahn

Since Specialization
Citations

This map shows the geographic impact of M-J. Ahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M-J. Ahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M-J. Ahn more than expected).

Fields of papers citing papers by M-J. Ahn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M-J. Ahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M-J. Ahn. The network helps show where M-J. Ahn may publish in the future.

Co-authorship network of co-authors of M-J. Ahn

This figure shows the co-authorship network connecting the top 25 collaborators of M-J. Ahn. A scholar is included among the top collaborators of M-J. Ahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M-J. Ahn. M-J. Ahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ferrara, Roberto, Xiaobing Le, Hiroya Sakai, et al.. (2025). 81P: Tepotinib in patients (pts) with METexon 14 (METex14) skipping non-small cell lung cancer (NSCLC) from the VISION study: ≥3-year follow-up outcomes. Journal of Thoracic Oncology. 20(3). S59–S60.
2.
3.
4.
5.
Yamamoto, Noboru, Hai‐Yan Tu, M-J. Ahn, et al.. (2024). LBA5 Zongertinib in patients with HER2-mutant NSCLC: Updated analysis of beamion LUNG-1. Annals of Oncology. 35. S1623–S1624. 3 indexed citations
6.
7.
Ahn, M-J., Ibiayi Dagogo‐Jack, Francesco Gelsomino, et al.. (2024). LBA56 Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). Annals of Oncology. 35. S1246–S1247. 2 indexed citations
8.
9.
10.
Viteri, Santiago, Enriqueta Felip, Frank Griesinger, et al.. (2023). 1380P Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial. Annals of Oncology. 34. S791–S792. 3 indexed citations
11.
Kitazono, Satoru, Luis Paz‐Ares, M-J. Ahn, et al.. (2023). 518MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs). Annals of Oncology. 34. S1671–S1672. 8 indexed citations
12.
Paz‐Ares, Luis, M-J. Ahn, Enriqueta Felip, et al.. (2023). 508MO Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study. Annals of Oncology. 34. S1664–S1665. 1 indexed citations
13.
14.
Ho, Alan L., Douglas R. Adkins, George J. Hanna, et al.. (2023). LBA47 A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study). Annals of Oncology. 34. S1286–S1287. 4 indexed citations
15.
16.
17.
Dziadziuszko, Rafał, Salvatore Siena, Daniel S.W. Tan, et al.. (2020). 1288P Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline. Annals of Oncology. 31. S833–S834. 5 indexed citations
18.
Ahn, M-J., Jiaxin Niu, Dongwook Kim, et al.. (2020). 1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC. Annals of Oncology. 31. S887–S887. 26 indexed citations
19.
Tan, Daniel Shao-Weng, M-J. Ahn, Herbert H. Loong, et al.. (2020). 299MO Efficacy and safety of entrectinib in an Asian population with NTRK fusion-positive (fp) solid tumours or ROS1-fp NSCLC. Annals of Oncology. 31. S1358–S1359. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eduardo J. Pennella Breakdown of academic impact, for papers by Emily Roarty Breakdown of academic impact, for papers by Virginia Palomar Coloma Breakdown of academic impact, for papers by Sufia Safina Breakdown of academic impact, for papers by Maria Bassanelli Breakdown of academic impact, for papers by Beung‐Chul Ahn Breakdown of academic impact, for papers by María Gión Breakdown of academic impact, for papers by Nathan Comeaux Breakdown of academic impact, for papers by A. Sandler Breakdown of academic impact, for papers by L. Bouhlel
Rankless by CCL
2026